The strong underlying sales growth and raised guidance are positive for the stock, but the large amlitelimab impairment and pipeline discontinuation introduce uncertainty. Monitor the venglustat FDA decision (target date Nov 25, 2026) and upcoming dupixent LSC data for further pipeline catalysts. The revenue beat and guidance hike support near-term upside, but the impairment overhang may cap gains.
Price Chart
Executive Summary
Sanofi reported H1 2026 net sales of €22,106M (+11.1% reported, +15.7% CER), driven by Dupixent (+34.4% CER) and new launches. Business EPS rose 17.1% to €3.97, and guidance was raised to ~10% CER sales growth for FY2026, with Business EPS growing slightly faster. However, IFRS net income fell 66.3% to €1,957M, largely due to a €1,031M impairment (€952M for discontinued amlitelimab) and the prior-year Opella divestiture gain. The underlying business performance is strong, but the pipeline setback and elevated restructuring costs temper the outlook.
Key Facts
- H1 2026 net sales: €22,106M, +11.1% reported, +15.7% CER vs H1 2025
- Business EPS: €3.97, +17.1% vs €3.39 in H1 2025
- IFRS net income attributable to equity holders: €1,957M, down from €5,812M (H1 2025 included €2,693M Opella gain)
- Dupixent sales: €9,324M, +27.5% reported, +34.4% CER
- €1,031M impairment of intangible assets, primarily €952M for amlitelimab (pipeline discontinuation)
- Restructuring costs: €563M, up from €430M in H1 2025
- Net debt: €15,513M, gearing 22.3% vs 15.4% at Dec 2025
- Free cash flow: €3,724M, up from €2,458M in H1 2025
- Completed acquisition of Dynavax for ~$2.2B, including HEPLISAV-B and shingles vaccine candidate
- FY2026 guidance raised: net sales growth ~10% CER, Business EPS growing slightly faster
Financial Impact
Underlying business net income up 14.8% to €4,765M, but IFRS net income down 66.3% due to impairment and prior-year gain. FY2026 guidance raised.
Risk Factors
- Amlitelimab discontinuation and pipeline setbacks in atopic dermatitis/COPD may raise questions about R&D productivity
- Net debt increased sharply, and gearing rose to 22.3%, potentially limiting flexibility for further M&A
- Restructuring costs remain elevated, and currency headwinds (-4.6% on sales) persist
- Competitive pressure on Dupixent (new entries) and vaccines (declining COVID/influenza sales)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-050803 |
| Exhibit: exhibit992-2026halfyearman.htm | 0001628280-26-050803 |
| Document: sny-20260630.htm | 0001628280-26-050803 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Court Ruling | $44.36 $40.74 | ▼ −8.16% | ▼ −7.97% | $39.92 (−10.01%) |
Aug 17, 2026 6w ago | Court Ruling | $44.41 $42.40 | ▼ −4.53% | ▼ −2.55% | $39.92 (−10.11%) |
Aug 12, 2026 7w ago | Court Ruling | $43.71 $42.72 | ▼ −2.26% | ▼ −0.37% | $39.92 (−8.67%) |
Jul 31, 2026 9w ago | Court Ruling | $43.08 $44.82 | ▲ +4.04% | ▲ +1.05% | $39.92 (−7.34%) |
Jul 30, 2026 9w ago | 6-K | $42.89 $44.84 | ▲ +4.55% | ▲ +0.58% | $39.92 (−6.92%) |
Jul 27, 2026 9w ago | 6-K | $44.00 $45.69 | ▼ −3.84% | ▼ −0.54% | $39.92 (+9.27%) |
Jul 17, 2026 11w ago | 6-K | $44.66 $43.72 | ▼ −2.10% | ▼ −6.55% | $39.92 (−10.61%) |
Jul 7, 2026 12w ago | 6-K | $42.98 $42.95 | ▼ −0.07% | ▼ −1.40% | $39.92 (−7.12%) |
Apr 13, 2026 24w ago | Court Ruling | $44.49 $42.50 | ▼ −4.48% | ▼ −12.20% | $39.92 (−10.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access